Experimental combo targets STK11-Deficient lung cancer

NCT ID NCT06219174

Terminated Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 1/2 trial tests whether adding difluoromethylornithine (DFMO) to the immunotherapy pembrolizumab (Keytruda) is safe and effective for people with advanced non-small cell lung cancer that has a specific genetic change (STK11/LKB1 deficiency). About 45 participants will receive the combination. The study aims to find the best dose and measure tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Difluoromethylornithine (DFMO) combined with pembrolizumab (Keytruda)
What this could lead to: If successful, this could offer a new treatment option for a hard-to-treat form of lung cancer that lacks the STK11 gene.
What could go wrong: This is an early-phase trial with only 45 participants, so results may not apply broadly. The study is currently suspended, and the combination may cause side effects without improving outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung cancer lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG CANCER NON-SMALL CELL LUNG CANCER

Contacts and locations

Locations

Moffitt Cancer Center

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.